<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290873</url>
  </required_header>
  <id_info>
    <org_study_id>CNS7056-006</org_study_id>
    <nct_id>NCT02290873</nct_id>
  </id_info>
  <brief_title>A Phase III Study of the Efficacy and Safety of Remimazolam Compared to Placebo and Midazolam in Colonoscopy Patients</brief_title>
  <official_title>A Prospective, Double-blind, Randomized, Placebo and Active Controlled, Multi-center, Parallel Group Study Comparing Remimazolam to Placebo, With an Additional Open-label Arm For Midazolam, in Patients Undergoing a Colonoscopy for Diagnostic or Therapeutic Reasons.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Paion UK Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research Group plc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Paion UK Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, double-blind, randomized, placebo and active controlled, multi-center,
      parallel group study comparing remimazolam to placebo, with an additional open-label arm for
      midazolam, in patients undergoing a colonoscopy for diagnostic or therapeutic reasons.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Actual">April 19, 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of Procedure</measure>
    <time_frame>From administration of the first dose of the study drug to the end of colonoscopy</time_frame>
    <description>Measured by completion of colonoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period in the blinded arms (remimazolam/placebo) or no requirement for more than 3 doses within any 12 minute window in the midazolam arm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Start of Procedure</measure>
    <time_frame>From first dose of study drug until insertion of the colonoscope</time_frame>
    <description>The time to the start of the procedure after administration of the first dose of randomized study drug</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Fully Alert</measure>
    <time_frame>From the end of colonoscopy (colonoscope out) until the patient has recovered to fully alert and from the last injection of the study drug or rescue sedative medication until the patient has recovered to fully alert</time_frame>
    <description>The time to fully alert (time to first of three consecutive Modified Observer's Assessment of Alertness/Sedation [MOAA/S] scores of 5) after the end of colonoscopy procedure [colonoscope out], and after the last dose of study drug or rescue sedative medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ready for Discharge</measure>
    <time_frame>From the end of the colonoscopy until discharge (expected to be the same day). After the last dose of study drug or rescue sedative, until discharge (expected to be the same day).</time_frame>
    <description>The time after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug or rescue sedative medication, until discharge (defined as ability to walk unassisted).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Colonoscopy</condition>
  <arm_group>
    <arm_group_label>Remimazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Remimazolam iv 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo iv for sedation induction and maintenance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Midazolam iv 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remimazolam</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Remimazolam</arm_group_label>
    <other_name>CNS7056</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>For induction of maintenance and sedation</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>For induction and maintenance of sedation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients, aged ≥18, scheduled to undergo a diagnostic or therapeutic
             colonoscopy (therapeutic procedures could include hemostasis, resection, ablation
             decompression, foreign body extraction, for example).

          -  American Society of Anesthesiologists Score 1 through 3

          -  Body mass index ≤40 kg/m2.

          -  For female patients with child-bearing potential, negative result of pregnancy test
             (serum or urine) as well as use of birth control during the study period (from the
             time of consent until all specified observations were completed).

          -  Patient voluntarily signed and dated an informed consent form that was approved by an
             Independent Review Board prior to the conduct of any study procedure.

          -  Patient was willing and able to comply with study requirements and return for a
             Follow-up Visit on Day 4 (+3/-1 days) after the colonoscopy.

        Exclusion Criteria:

          -  Patients with a known sensitivity to benzodiazepines, flumazenil, opioids, naloxone,
             or a medical condition such that these agents were contraindicated.

          -  Chronic use of benzodiazepines for any indication (eg, insomnia, anxiety, spasticity).

          -  Chronic use of opioids for any indication.

          -  Female patients with a positive serum human chorionic gonadotropin pregnancy test at
             screening or baseline.

          -  Lactating female patients.

          -  Patients with positive drugs of abuse screen or a positive serum ethanol at baseline.

          -  Patient with a history of drug or ethanol abuse within the past 2 years.

          -  Patients in receipt of any investigational drug within 30 days or less than seven
             half-lives (whichever was longer) before screening, or scheduled to receive one during
             the study period.

          -  Participation in any previous clinical trial with remimazolam.

          -  Patients with an inability to communicate well in English with the investigator, or
             deemed unsuitable according to the investigator (in each case providing a reason).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Douglas K Rex, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36688</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Borland-Grover Clinic, P.A</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners Inc</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Medical College</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nashville Medical Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Tidewater</name>
      <address>
        <city>Chesapeake</city>
        <state>Virginia</state>
        <zip>23320</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.</citation>
    <PMID>22190555</PMID>
  </reference>
  <reference>
    <citation>Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012 Aug;115(2):284-96. doi: 10.1213/ANE.0b013e318241f68a. Epub 2012 Jan 16.</citation>
    <PMID>22253270</PMID>
  </reference>
  <reference>
    <citation>Worthington MT, Antonik LJ, Goldwater DR, Lees JP, Wilhelm-Ogunbiyi K, Borkett KM, Mitchell MC. A phase Ib, dose-finding study of multiple doses of remimazolam (CNS 7056) in volunteers undergoing colonoscopy. Anesth Analg. 2013 Nov;117(5):1093-100. doi: 10.1213/ANE.0b013e3182a705ae.</citation>
    <PMID>24108261</PMID>
  </reference>
  <reference>
    <citation>Borkett KM, Riff DS, Schwartz HI, Winkle PJ, Pambianco DJ, Lees JP, Wilhelm-Ogunbiyi K. A Phase IIa, randomized, double-blind study of remimazolam (CNS 7056) versus midazolam for sedation in upper gastrointestinal endoscopy. Anesth Analg. 2015 Apr;120(4):771-80. doi: 10.1213/ANE.0000000000000548.</citation>
    <PMID>25502841</PMID>
  </reference>
  <reference>
    <citation>Pambianco DJ, Borkett KM, Riff DS, Winkle PJ, Schwartz HI, Melson TI, Wilhelm-Ogunbiyi K. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2016 May;83(5):984-92. doi: 10.1016/j.gie.2015.08.062. Epub 2015 Sep 9.</citation>
    <PMID>26363333</PMID>
  </reference>
  <results_reference>
    <citation>Douglas K. Rex, MD, MACG, Raj Bhandari, MD, Taddese Desta MD, Michael DeMicco MD, Cynthia Schaeffer MD, Kyle Etzkorn, Charles Barish MD, Ronald Pruitt MD, Brooks Cash MD, FACG, Daniel Quirk MD, Felix Tiongco MD, David Bernstein MD, FACG. REMIMAZOLAM IS A SAFE AND EFFECTIVE AGENT FOR SEDATION IN OUTPATIENT COLONOSCOPY: RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, PLACEBO CONTROLLED TRIAL. Program No. ACG 2016 Annual Scientific Meeting Abstracts. Las Vegas, NV: American College of Gastroenterology.</citation>
  </results_reference>
  <results_reference>
    <citation>Rex DK, Bhandari R, Desta T, DeMicco MP, Schaeffer C, Etzkorn K, Barish CF, Pruitt R, Cash BD, Quirk D, Tiongco F, Sullivan S, Bernstein D. A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy. Gastrointest Endosc. 2018 Sep;88(3):427-437.e6. doi: 10.1016/j.gie.2018.04.2351. Epub 2018 Apr 30.</citation>
    <PMID>29723512</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>November 7, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>October 10, 2018</results_first_submitted>
  <results_first_submitted_qc>October 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 9, 2018</results_first_posted>
  <last_update_submitted>October 10, 2018</last_update_submitted>
  <last_update_submitted_qc>October 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Remimazolam</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Double-blind Placebo iv arm: as an inactive control</description>
        </group>
        <group group_id="P3">
          <title>Midazolam</title>
          <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="298"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="103"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Modified Intention to Treat (mITT)</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="296"/>
                <participants group_id="P2" count="59"/>
                <participants group_id="P3" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Nellcor device error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Esophagogastroduodenoscopy was added</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Analysis Population is the safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Remimazolam</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Double-blind Placebo iv arm: inactive control arm</description>
        </group>
        <group group_id="B3">
          <title>Midazolam</title>
          <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="296"/>
            <count group_id="B2" value="60"/>
            <count group_id="B3" value="102"/>
            <count group_id="B4" value="458"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.4" spread="10.12"/>
                    <measurement group_id="B2" value="56" spread="9.51"/>
                    <measurement group_id="B3" value="55.6" spread="10.15"/>
                    <measurement group_id="B4" value="54.9" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="88"/>
                    <measurement group_id="B4" value="395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="56"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="147"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="296"/>
                    <measurement group_id="B2" value="60"/>
                    <measurement group_id="B3" value="102"/>
                    <measurement group_id="B4" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.2" spread="17.39"/>
                    <measurement group_id="B2" value="84.6" spread="19.9"/>
                    <measurement group_id="B3" value="81.9" spread="16.24"/>
                    <measurement group_id="B4" value="83.1" spread="17.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="170.1" spread="10.36"/>
                    <measurement group_id="B2" value="167.8" spread="10.24"/>
                    <measurement group_id="B3" value="169.5" spread="11.15"/>
                    <measurement group_id="B4" value="169.6" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Max Index (BMI)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="4.72"/>
                    <measurement group_id="B2" value="30" spread="5.31"/>
                    <measurement group_id="B3" value="28.8" spread="4.75"/>
                    <measurement group_id="B4" value="29" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success of Procedure</title>
        <description>Measured by completion of colonoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period in the blinded arms (remimazolam/placebo) or no requirement for more than 3 doses within any 12 minute window in the midazolam arm.</description>
        <time_frame>From administration of the first dose of the study drug to the end of colonoscopy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Placebo iv arm: as an inactive control arm</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
          </group>
        </group_list>
        <measure>
          <title>Success of Procedure</title>
          <description>Measured by completion of colonoscopy, no requirement for an alternative sedative and no requirement for more than 5 top-ups of study medication within any 15 minute period in the blinded arms (remimazolam/placebo) or no requirement for more than 3 doses within any 12 minute window in the midazolam arm.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="298"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="272"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value calculated from a Cochran-Mantel-Haenszel test accounting for fentanyl strata.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.8961</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8505</ci_lower_limit>
            <ci_upper_limit>0.9416</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Start of Procedure</title>
        <description>The time to the start of the procedure after administration of the first dose of randomized study drug</description>
        <time_frame>From first dose of study drug until insertion of the colonoscope</time_frame>
        <population>Patients who do not reach the endpoint are excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Placebo iv arm: as an inactive control arm</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Start of Procedure</title>
          <description>The time to the start of the procedure after administration of the first dose of randomized study drug</description>
          <population>Patients who do not reach the endpoint are excluded from the analysis.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3.0" upper_limit="6.0"/>
                    <measurement group_id="O2" value="19.5" lower_limit="17.0" upper_limit="23.0"/>
                    <measurement group_id="O3" value="19" lower_limit="12.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>6.133</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.416</ci_lower_limit>
            <ci_upper_limit>8.517</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fully Alert</title>
        <description>The time to fully alert (time to first of three consecutive Modified Observer's Assessment of Alertness/Sedation [MOAA/S] scores of 5) after the end of colonoscopy procedure [colonoscope out], and after the last dose of study drug or rescue sedative medication</description>
        <time_frame>From the end of colonoscopy (colonoscope out) until the patient has recovered to fully alert and from the last injection of the study drug or rescue sedative medication until the patient has recovered to fully alert</time_frame>
        <population>Patients who do not reach the endpoint are censored at last MOAA/S</population>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Placebo iv arm: as an inactive control</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fully Alert</title>
          <description>The time to fully alert (time to first of three consecutive Modified Observer's Assessment of Alertness/Sedation [MOAA/S] scores of 5) after the end of colonoscopy procedure [colonoscope out], and after the last dose of study drug or rescue sedative medication</description>
          <population>Patients who do not reach the endpoint are censored at last MOAA/S</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After the end of colonoscopy</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="293"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="101"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="5" upper_limit="7"/>
                    <measurement group_id="O2" value="15" lower_limit="13" upper_limit="21"/>
                    <measurement group_id="O3" value="13" lower_limit="11" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose of study drug or rescue sedative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="296"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14" lower_limit="13" upper_limit="14"/>
                    <measurement group_id="O2" value="28" lower_limit="24" upper_limit="32"/>
                    <measurement group_id="O3" value="24" lower_limit="22" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ready for Discharge</title>
        <description>The time after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug or rescue sedative medication, until discharge (defined as ability to walk unassisted).</description>
        <time_frame>From the end of the colonoscopy until discharge (expected to be the same day). After the last dose of study drug or rescue sedative, until discharge (expected to be the same day).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Remimazolam</title>
            <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Double-blind Placebo iv arm: as an inactive control arm</description>
          </group>
          <group group_id="O3">
            <title>Midazolam</title>
            <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ready for Discharge</title>
          <description>The time after the end of colonoscopy procedure (colonoscope out) and after the last injection of study drug or rescue sedative medication, until discharge (defined as ability to walk unassisted).</description>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="296"/>
                <count group_id="O2" value="60"/>
                <count group_id="O3" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>After the end of colonoscopy procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="42" upper_limit="46"/>
                    <measurement group_id="O2" value="49" lower_limit="44" upper_limit="54"/>
                    <measurement group_id="O3" value="48" lower_limit="41" upper_limit="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After last dose of study drug or rescue sedative</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="49" upper_limit="54"/>
                    <measurement group_id="O2" value="60.5" lower_limit="55" upper_limit="67"/>
                    <measurement group_id="O3" value="57" lower_limit="53" upper_limit="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug until Day 4, or resolution of any ongoing adverse events</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Remimazolam</title>
          <description>Double-blind Remimazolam iv arm: 5 mg for sedation induction, and 2.5 mg top-ups for sedation maintenance.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Double-blind Placebo iv arm: as an inactive control</description>
        </group>
        <group group_id="E3">
          <title>Midazolam</title>
          <description>Open-label Midazolam iv arm: 1.75 mg* for sedation induction and 1.0 mg* for sedation maintenance.
*1.0 mg for induction and 0.5 mg for maintenance in adults over 60, debilitated or chronically ill</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="218" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="115" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diastolic Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Diastolic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Systolic hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="296"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="60"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>At least 60 days prior to submission of communications, sponsor shall review and comment on the communications. Sponsor shall have the right to require institution and investigator to remove specifically identified confidential information and to delay the proposed publication an additional 60 days to enable sponsor to seek patent protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Information</name_or_title>
      <organization>PAION UK Ltd</organization>
      <phone>+49 2414453101</phone>
      <email>reg_paion@paion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

